Indications:¹

Early breast cancer (eBC)

KISQALI, in combination with an aromatase inhibitor (AI), is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative eBC at high risk of recurrence (see section 5.1 of the SmPC for selection criteria).

• In pre- or perimenopausal women, or in men, the AI should be combined with a luteinising hormone-releasing hormone (LHRH) agonist

Advanced or metastatic breast cancer (aBC) 

KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer (aBC) in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy (ET).

• In pre- or perimenopausal women, the ET should be combined with a luteinising hormone-releasing hormone (LHRH) agonist

KISQALI is not recommended to be used in combination with tamoxifen.

KISQALI Summary of Product Characteristics (SmPC) can be found here.

Please consult your local SmPC for the full KISQALI safety and tolerability profile.

Explore our resources below, designed to support healthcare professionals with KISQALI in both eBC and aBC. You can preview and download any of these tools to use in your own time.

To receive more information or any printed copies available, please contact your Novartis representative.